Status:
COMPLETED
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
Lead Sponsor:
Pfizer
Conditions:
Pneumococcal Vaccines
Eligibility:
All Genders
140-392 years
Phase:
PHASE3
Brief Summary
The purposes of this study are to evaluate the safety of 13-valent pneumococcal Conjugate Vaccine (13vPnC) in children who have already been vaccinated with Prevenar. The study will also assess the im...
Eligibility Criteria
Inclusion
- Healthy children previously immunized with 1 or 2 doses of Prevenar.
- Group 1: Male or female subjects between the age of \>=140 and \<=196 days of age at time of enrollment.
- Group 2: Male or female subjects between the age of \>=336 and \<=392 days of age at time of enrollment
- Available for entire study period.
Exclusion
- Previous reaction or contra-indication to pneumococcal vaccine or vaccine related component.
- Previous vaccination with licensed or investigational pneumococcal vaccine other than Prevenar.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
234 Patients enrolled
Trial Details
Trial ID
NCT00824655
Start Date
March 1 2009
End Date
June 1 2010
Last Update
August 10 2011
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Eskilstuna, Sweden, SE-63188
2
Pfizer Investigational Site
Gothenburg, Sweden, SE-40014
3
Pfizer Investigational Site
Malmo, Sweden, SE-20502
4
Pfizer Investigational Site
Örebro, Sweden, SE-70185